A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs Efpeglenatide (Primary) ; Liraglutide
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EXCEED; EXCEED 203
- Sponsors Hanmi Pharmaceutical
- 18 Jul 2019 Safety and efficacy results published in the Diabetes Care.
- 11 Jun 2019 Results of post-hoc sub analysis stratified by baseline characteristics, presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Subanalysis results from EXCEED 203 study were presented at the 79th Annual Scientific Sessions of the American Diabetes Association.